Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.
2.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947.

PMID:
11874944
3.

Serum lipids and glucose control: the SEARCH for Diabetes in Youth study.

Petitti DB, Imperatore G, Palla SL, Daniels SR, Dolan LM, Kershnar AK, Marcovina S, Pettitt DJ, Pihoker C; SEARCH for Diabetes in Youth Study Group.

Arch Pediatr Adolesc Med. 2007 Feb;161(2):159-65.

PMID:
17283301
4.
5.

Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes.

Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR.

Diabetes Res Clin Pract. 2007 Aug;77(2):180-7. Epub 2007 Jan 18.

PMID:
17239474
7.

Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes.

Albers JJ, Marcovina SM, Imperatore G, Snively BM, Stafford J, Fujimoto WY, Mayer-Davis EJ, Petitti DB, Pihoker C, Dolan L, Dabelea DM.

J Clin Endocrinol Metab. 2008 Mar;93(3):735-42. Epub 2007 Dec 18.

8.

Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.

Navarro JF, Mora C, Muros M, García-Idoate G.

Nephron Clin Pract. 2003;95(4):c128-35.

PMID:
14694274
9.

Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes.

Berneis K, Jeanneret C, Muser J, Felix B, Miserez AR.

Metabolism. 2005 Feb;54(2):227-34.

PMID:
15690318
10.

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators.

Diabetes Care. 2005 Jul;28(7):1547-54.

PMID:
15983299
11.
13.

The effects of resistance training on ApoB/ApoA-I ratio, Lp(a) and inflammatory markers in patients with type 2 diabetes.

Kadoglou NP, Fotiadis G, Athanasiadou Z, Vitta I, Lampropoulos S, Vrabas IS.

Endocrine. 2012 Dec;42(3):561-9. doi: 10.1007/s12020-012-9650-y. Epub 2012 Mar 11.

PMID:
22407494
14.

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

Taskinen MR, Barter PJ, Ehnholm C, Sullivan DR, Mann K, Simes J, Best JD, Hamwood S, Keech AC; FIELD study investigators.

Diabetologia. 2010 Sep;53(9):1846-55. doi: 10.1007/s00125-010-1806-9. Epub 2010 Jun 6.

PMID:
20526762
15.

Hypertriglyceridemic hyperapoB in type 2 diabetes.

Sniderman AD, Lamarche B, Tilley J, Seccombe D, Frohlich J.

Diabetes Care. 2002 Mar;25(3):579-82.

PMID:
11874951
16.

The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes.

Erdman DM, Cook CB, Greenlund KJ, Giles WH, El-Kebbi I, Ryan GJ, Gallina DL, Ziemer DC, Dunbar VG, Phillips LS.

Diabetes Care. 2002 Jan;25(1):9-15.

PMID:
11772894
18.

Relationship of highly sensitive C-reactive protein and lipid levels in adolescents with type 1 diabetes mellitus.

Karantza MV, Mittelman SD, Dorey F, Samie S, Kaiserman K, Halvorson M, Kaufman FR.

Pediatr Diabetes. 2008 Apr;9(2):122-6. Epub 2007 Nov 23.

PMID:
18036131
19.
20.

Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control.

Tan CE, Chew LS, Chio LF, Tai ES, Lim HS, Lim SC, Jayakumar L, Eng HK, Packard CJ.

Diabetes Res Clin Pract. 2001 Feb;51(2):107-14.

PMID:
11165690
Items per page

Supplemental Content

Write to the Help Desk